👉️ Take the Small Cell Lung Cancer ONCO-IQ quiz - bit.ly/SCLC-ONCO-IQ This peer-reviewed ONCO-IQ quiz is designed for oncology professionals, a fast, high-yield knowledge check you can complete in minutes.

🚨 Latest #FDA Approval Update! 🔷 U.S. FDA approves Optune Pax® for first-line treatment of locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, the first new FDA-approved therapy in nearly 30 years for this setting.

🚨 Latest #FDA Approval Update! 🔷 Agilent’s PD-L1 IHC 22C3 pharmDx receives FDA approval for use in epithelial ovarian, fallopian tube, and primary peritoneal carcinoma (EOC).

🚨 Latest #FDA Approval Update! 🔷 FDA approves pembrolizumab-based therapy + paclitaxel (± bevacizumab) for PD-L1+ platinum-resistant ovarian and related cancers after prior treatment.

🚨 Latest #FDA Update! 🔷 Median Technologies has received FDA 510(k) clearance for eyonis® LCS (Lung Cancer Screening), the first AI-based medical device cleared for lung cancer detection and diagnosis in a screening setting, supporting earlier and more accurate identification of disease.

🚨 Latest #Phase 3 Trial Update! 🔷 Nuvation Bio has initiated the pivotal, global Phase 3 SIGMA (G203) trial evaluating safusidenib, an oral, brain-penetrant IDH1 inhibitor, in patients with IDH1-mutant glioma, aiming to address a high unmet need in this molecularly defined population.

🚨 Latest #FDA Approval Update! 🔷 The FDA has approved a label update for Kite Pharma’s Yescarta® (axicabtagene ciloleucel), expanding its indication to include adults with relapsed or refractory primary central nervous system (CNS) lymphoma.

👉Take the Early Breast Cancer ONCO-IQ quiz now - bit.ly/EBC_ONCO_IQ_X This peer-reviewed ONCO-IQ quiz is designed for oncology professionals, a fast, high-yield knowledge check you can complete in minutes. #Chemotherapy #Oncology #OncoIQ #MedicalEducation #CancerCare #OncologyTraining

🚨 Latest #ClinicalTrial Update! 🔷 10-year data from HYPO-RT-PC show ultra-hypofractionated radiotherapy remains non-inferior to conventional fractionation for localised prostate cancer

🚨 Latest ASCO #Guideline Update! 🔷 The ASCO Living Guideline (2026.3.0) provides an updated framework for the systemic management of stage IV non–small cell lung cancer (NSCLC) without driver alterations, reflecting the rapidly evolving treatment landscape.

🚨 Latest ASCO #Guideline Update! 🔷 The ASCO Living Guideline (2026.3.0) outlines evolving systemic therapy strategies for patients with stage IV non–small cell lung cancer (NSCLC) with driver alterations, including treatment intensification for selected subgroups and newly approved agents.

🚨 Latest #Approval Update! 🔷 Nubeqa™(darolutamide) receives its third approval in China for men with advanced prostate cancer, becoming the only androgen receptor inhibitor approved for metastatic hormone-sensitive prostate cancer with androgen deprivation therapy with or without chemotherapy.

🚨 Latest #Oncology Update! 🔷 Five-year follow-up from China’s CAPTAIN-1st trial demonstrated durable survival benefit with camrelizumab plus chemotherapy in recurrent/metastatic nasopharyngeal carcinoma.

🚨 Latest #Oncology Update! 🔷 In the PREOPANC-2 trial, venous thromboembolism (VTE) occurred in 28/325 patients (9%) within 12 months post-randomisation, 3% during preoperative therapy and 8% postoperatively during adjuvant treatment, highlighting risk across the full perioperative period.

🚨 Latest #Oncology Update! 🔷 A tissue-free, epigenomic ctDNA assay detected molecular residual disease (MRD) after surgery in patients with stage III colon cancer enrolled in Alliance N0147, a phase III adjuvant FOLFOX trial.

👉 Take the Oesophageal cancers ONCO-IQ quiz in collaboration with HemOnc Fellows Network - bit.ly/HemOnc_ONCO_... This peer-reviewed ONCO-IQ quiz is designed for oncology professionals, a fast, high-yield knowledge check you can complete in minutes.

🚨 Latest #FDAApproval Update! 🔷 FDA grants Fast Track designation to QTX-2101, an investigational oral arsenic trioxide capsule targeting acute promyelocytic leukemia (APL), a rare, rapidly progressive acute myeloid leukemia (AML) subtype with high bleeding risk.

🚨 The latest #Oncology Update! 🔷 The Phase III DELII trial assesses the efficacy and safety of ultra-low dose immunotherapy in relapsed or refractory solid tumors.

🚨 The latest #Oncology Update! 🔷 Palbociclib in hormone receptor–positive, HER2-positive advanced breast cancer highlights a promising strategy for this dual-positive subtype.

🚨 The New #FDAApproval Alert! 🔹 Shorla Oncology® receives U.S. FDA approval for a larger vial size of nelarabine for IV treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).

🚨 The latest #FDAApproval Alert! 🔹 FDA approved daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide, and dexamethasone (DARZALEX FASPRO-VRd) for patients with newly diagnosed multiple myeloma.

🚨 The latest Phase 3 Trial Update! 🔹 Corcept’s Phase 3 ROSELLA trial met its primary OS endpoint with relacorilant in platinum-resistant ovarian cancer. 🔹 Relacorilant demonstrated a 35% OS improvement and met primary endpoints, with NDA under FDA review and MAA under EMA review.

🚨 The latest #FDAApproval Alert! 🔹 Guardant Health’s Guardant360® CDx is now FDA-approved as a companion diagnostic for BRAFTOVI® (encorafenib)–based therapy in patients with BRAF V600E-mutant metastatic colorectal cancer.

🚨 The latest #Oncology Update! 🔹 Moderna & Merck share 5-year data showing intismeran autogene + KEYTRUDA® (pembrolizumab) delivers sustained improvement in recurrence-free survival (RFS) for patients with high-risk stage III/IV melanoma after complete resection.

👉 Take the 2025 in Oncology - some Insights and Advances ONCO-IQ quiz now - bit.ly/2025Insights... This peer-reviewed ONCO-IQ quiz is designed for oncology professionals, a fast, high-yield knowledge check you can complete in minutes.

🚨 The Randomized Phase II/III Trial Update! 🔹 The JCOG0603 trial evaluated hepatectomy followed by adjuvant mFOLFOX6 vs. hepatectomy alone in patients with colorectal liver metastasis. 🔹 Long-term results show improved DFS with adjuvant mFOLFOX6, but no significant OS benefit compared with surgery

🎗️The latest Phase 3 Trial Update! 🔹 Sacituzumab Govitecan + Pembrolizumab is being evaluated as a promising combination for patients with advanced triple-negative breast cancer.

🎗️The latest #Oncology Update! ▪️ Agendia announced an NCCN guideline update recognizing MammaPrint® to help guide personalized anthracycline use in patients with HR+/HER2− Early-Stage Breast Cancer.

🚨 The latest #Oncology Update! ▪️ ASCO has released Version 2026.1 of the Living Guideline for systemic therapy in metastatic castration-resistant prostate cancer, reflecting the latest evidence-based recommendations for care.

🎗️The latest #Oncology Study Update! ▪️ SERENA-3 Study Insights: Camizestrant showed clear pharmacodynamic activity in postmenopausal women with ER+, HER2 primary breast cancer in a randomized presurgical setting.

🚨The latest Phase 3 Trial Update! ▪️ AbbVie reports topline Phase 3 EPCORE® DLBCL-1 results for epcoritamab in R/R DLBCL, advancing evidence for CD3xCD20 bispecific therapy. ▪️ Subcutaneous epcoritamab improved PFS vs chemoimmunotherapy (HR 0.74), with higher complete responses.

👉 Take the Mechanisms of action & toxicities of chemotherapy ONCO-IQ quiz now - bit.ly/CMT-ONCO-IQ-X This peer-reviewed ONCO-IQ quiz is designed for oncology professionals, a fast, high-yield knowledge check you can complete in minutes.

🚨The Latest Saudi FDA Approval Alert! ✅ Saudi Food and Drug Authority (SFDA) has granted accelerated approval to ImmunityBio’s ANKTIVA® (nogapendekin alfa inbakicept)) for non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ.

🚨The Latest Saudi FDA Approval Alert! ✅ Saudi Food and Drug Authority (SFDA) has granted accelerated approval to ImmunityBio’s ANKTIVA® (nogapendekin alfa inbakicept) in combination with checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC).

🚨BREAKING: 🧬 ImmunityBio reported positive results showing ANKTIVA® as a lymphocyte-stimulating agent when combined with CPI in NSCLC. 📈 Across 2 trials, ANKTIVA® + CPI significantly restored lymphocyte counts and was associated with improved OS, with a phase 3 confirmatory study ongoing.

🚨New #Oncology Trial Update! 🫁 NRG Oncology/Alliance LU005 evaluated chemoradiation with or without atezolizumab in patients with limited-stage SCLC. 📊 Adding atezolizumab did not improve OS, PFS, and DMFS vs chemoradiation alone, with no unexpected safety signals observed.

🚨Latest #Oncology Trial Update! 🫁 The BR.31 trial evaluated adjuvant durvalumab in patients with completely resected early-stage non-small cell lung cancer(NSCLC). 📉After 5 years of follow-up, durvalumab showed no DFS benefit over placebo in EGFR–/ALK– NSCLC and had more grade 3 - 4 side effects.

🚨Latest Phase III Trial Results! 🫁 Adjuvant Aumolertinib showed benefit with resected EGFR-mutated NSCLC in the phase 3 ARTS trial. 🧬As a 3rd-gen EGFR TKI, aumolertinib targets exon 19 grading deletion and exon 21 L858R mutations, addressing the high post-surgery recurrence risk in stage II–IIIB.

🚨New Phase III Trial update! 📈 In the phase 3 COMMIT study, FOLFOX + bevacizumab + atezolizumab improved PFS to 24.5 months vs 5.3 months with atezolizumab alone in dMMR/MSI-H mCRC. 💊 The combination also achieved a higher overall response rate (86.1% vs 46.0%). 🔗 Read more: bit.ly/ONCOnews12J-07

🚨Breaking GI #Oncology Update! ✅ Preoperative diffusion-weighted MRI reduced futile surgeries in colorectal peritoneal metastases from 42.5% to 26.8% in the DISCO trial. ⚖️ This imaging approach can help better select patients for cytoreductive surgery, minimizing unnecessary procedures and risks.

🚨Breaking GI #Oncology Update! ✅ Walking and regular physical activity after treatment can reduce cancer-related fatigue in colorectal cancer survivors. ⏳Activity at diagnosis does not predict long-term fatigue, highlighting the post-treatment recovery period as a key window for intervention.

🚨Breaking GI #Oncology Update! 🧬 Early studies in KRAS(G12D)-mutant PDAC show promising antitumor activity with targeted agents including INCB161734 and setidegrasib, with manageable safety profiles. 🔄 Responses were observed both alone and with chemotherapy, including mFOLFIRINOX.

🚨New #Oncology update! 📊 S1826 Trial: Nivolumab-AVD achieved high 3-year PFS in adolescents with advanced-stage classic Hodgkin lymphoma, with minimal use of radiotherapy. ✅ The trial highlights how harmonized trial designs can accelerate access to novel therapies for adolescent patients.

🚨New Phase III Trial update! 🔔 SCOT Phase III: Three months of adjuvant oxaliplatin–fluoropyrimidine was noninferior to six months, with identical 5-year overall survival (82.4%) in colorectal cancer (CRC).

🚨Latest #Oncology update! 🔬 BREAKWATER Cohort 3: Pfizer’s BRAFTOVI® (encorafenib) + ERBITUX® (cetuximab) + FOLFIRI (fluorouracil, leucovorin, and irinotecan) achieved a 64% Overall Response Rate (ORR) vs 39% with standard care in BRAF V600E-mutant metastatic colorectal cancer (mCRC).

🚨Breaking: 🔔 CRITICS-II: Preoperative chemotherapy + chemoradiotherapy showed outcomes vs either approach alone in resectable gastric cancer. 📈1-year EFS 84% and OS 89% with the combination, outperforming chemotherapy alone and chemoradiotherapy alone, supporting a strong neoadjuvant strategy.

🚨Breaking GI Oncology Update! 🧬 Phase II trial (China): Adding CAR-like T-cell therapy to first-line chemotherapy + immunotherapy significantly improved outcomes in metastatic gastric cancer and gastroesophageal junction adenocarcinoma (GC/GEJC).

🚨 Breaking GI Oncology Update! 📊 Phase III HERIZON-GEA-01: Zanidatamab + chemotherapy, with or without tislelizumab, significantly improved Progression-Free Survival (PFS) and Overall Survival (OS) versus trastuzumab-based therapy in HER2-positive advanced gastroesophageal adenocarcinoma (GEA).

🚨Latest Phase 3 Final Results! 📈 Upfront mFOLFOXIRI + panitumumab improved OS vs mFOLFOX + panitumumab in RAS/BRAF WT metastatic Colorectal Cancer. 👉 Survival benefit remained consistent across clinical subgroups in the Phase III TRIPLETE trial, supporting intensified first-line therapy.

👉 Take the Gastric Carcinoma ONCO-IQ quiz now - bit.ly/ONCO-IQ-GC This peer-reviewed ONCO-IQ quiz is designed for oncology professionals, a fast, high-yield knowledge check you can complete in minutes.